Cited by 591Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, Antoni, Camacho, Luis H., Lopez-Berestein, Gabriel, Pavlov, Dmitri, Bulanhagui, Cecile A., Millham, Robert, Comin-Anduix, Begoña, Reuben, James M., Seja, Elisabeth, Parker, Charla A., Sharma, Amarnath, Glaspy, John A., Gomez-Navarro, Jesus·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.109

Open this paper in CoChat — free account

Abstract

Purpose: Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective immune responses to cancer in humans. A phase I trial was conducted to test the safety of CP-675,206. Patients and Methods: Thirty-nine patients with solid malignancies (melanoma, n = 34; renal cell, n = 4; colon, n = 1) received an intravenous (IV) infusion of CP-675,206 at seven dose levels. The primary objective was to determine the maximum-tolerated dose and the recommended phase II dose. Results: Dose-limiting toxicities and autoimmune phenomena included diarrhea, dermatitis, vitiligo, panhypopituitarism and hyperthyroidism. Two patients experienced complete responses (maintained for 34+ and 25+ months), and there were two partial responses (26+ and 25+ months) among 29 patients with measurable melanoma. There have been no relapses thus far after objective response to therapy. Four other patients had stable disease at end of study evaluation (16, 7, 7, and 4 months). Additionally, five patients had extended periods without disease progression (36+, 35+, 26+, 24+, and 23+ months) after local treatment of progressive metastases. Longer systemic exposure to CP-675,206 achieved in higher dose cohorts predicted for a higher probability of response. Conclusion: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.109

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Show all 31 references

Sorted by citations

Items 401–500 of 591

Immunotherapy of Cancer
Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2017) · doi:10.1002/9781119468868.ch20 · Cited by 9
Monoclonal Serotherapy
Bast, R. C., Zalutsky, M. R., & Frankel, A. E. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm065 · Cited by 9
Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
Zhao, Y., Jiang, H., Xue, L., Zhou, M., Zhao, X., Liu, F., Jiang, S., Huang, J., & Meng, L. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01678-7 · Cited by 8
Targeted Therapy in Melanoma
Davies, M. A., Patel, S., & Kim, K. B. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_9 · Cited by 8
Pharmacokinetics and Pharmacodynamics of Immunotherapy
Lam, L. H., Lin, S., & Sun, J. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_2 · Cited by 8
Early Clinical Trial Experience with Vaccine Therapies in Non–Small-Cell Lung Cancer
Ho, C., Ochsenbein, A. F., Gautschi, O. P., & Davies, A. M. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.s.004 · Cited by 8
Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
Quesnel, B. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.6.773 · Cited by 8
Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer
Wang, J., Wang, S., Zhang, Y., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1329775 · Cited by 7
Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases
Tanhapour, M., Vaisi‐Raygani, A., Khazaei, M., Rahimi, Z., & Pourmotabbed, T. (2017) · AIMS Medical Science · doi:10.3934/medsci.2017.4.395 · Cited by 8
Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion.
Okawaki, M., Yamaguchi, Y., Okita, R., Ohara, M., & Okada, M. (2008) · PubMed · Cited by 7
Immunotherapy in Malignant Melanoma: Recent Approaches and New Perspectives
Arasanz, H., Lacalle, A., Lecumberri, M. J., de Lascoiti, Á. F., Blanco‐Luquin, I., Gato, M., Pérez-Ricarte, L., Zuazo, M., Kochan, G. T., & Escors, D. (2017) · Melanoma Management · doi:10.2217/mmt-2016-0019 · Cited by 7
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
von Itzstein, M. S., Yang, Y., Wang, Y., Hsiehchen, D., Sheffield, T. Y., Fattah, F. J., Popat, V., Ahmed, M., Homsi, J., Dowell, J. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1351739 · Cited by 6
Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma
Fujiwara, Y., Takahashi, Y., Okada, M., Kishimoto, T., Kondo, S., Fujikawa, K., Hayama, M., Sugeno, M., Ueda, S., Komuro, K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac099 · Cited by 6
Current Immunotherapeutic Strategies in Malignant Melanoma
Agostino, N. M., Ali, A., Nair, S., & Mosca, P. J. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.010 · Cited by 6
Targeted therapeutic strategies in malignant melanoma
Dietrich, S., & Kasper, B. (2008) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.04.008 · Cited by 6
Checkpoint Inhibition for Colorectal Cancer: Progress and Possibilities
Paul, B. A., O’Neil, B. H., & McRee, A. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0013 · Cited by 6
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
Somer, L. D., Fevery, S., Bullens, D. M. A., Rutgeerts, O., Lenaerts, C., Mathieu, C., Boon, L., Kasran, A., Waer, M., & Billiau, A. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.06.005 · Cited by 6
Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma
Margolin, K. A. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70470-3 · Cited by 6
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 6
[High circulating levels of adrenomedullin and endothelin-1 in obesity associated with arterial hypertension].
Letizia, C., Celi, M., Cerci, S., Scuro, L., Delfini, E., Subioli, S., Caliumi, C., & D'Erasmo, E. (2001) · PubMed · Cited by 6
Editorial
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992373 · Cited by 6
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
Wang, B., Xiao, B., Li, P., Kuang, B., Chen, W., Li, P., Lin, G., & Liu, Q. (2021) · Journal of Oncology · doi:10.1155/2021/3735726 · Cited by 6
Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6260 · Cited by 6
Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis
Han, X., Zhang, H., Sun, K., Li, J., Wu, W., Liu, K., & Yu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1302840 · Cited by 5
Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer
Zhou, Z., Li, K., Wei, Q., Chen, L., Shuai, Y., Wang, Y., He, K., Si, L., Zhong, Y., & Lu, J. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-572 · Cited by 5
Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
Li, W., Bi, Z., Wu, J., Duan, X., Pang, L., Jing, Y., Yin, X., & Cheng, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.772102 · Cited by 5
Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
Tang, J. P., Ma, X., Chen, X., Feng, M., Jin, X., Wang, K., Wan, J., Zhu, X., Xie, R., Dong, S., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3423 · Cited by 5
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Garon, E. B., Spira, A. I., Goldberg, S. B., Chaft, J. E., Papadimitrakopoulou, V. A., Cascone, T., Antonia, S. J., Brahmer, J. R., Camidge, D. R., Powderly, J. D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.020 · Cited by 5
Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
Melanoma Genel Bakış
Parlak, A. (2014) · Konuralp Tıp Dergisi · doi:10.18521/ktd.39906 · Cited by 5
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
Anstadt, E. J., Chu, B. K., Yegya‐Raman, N., Han, X., Doucette, A. G., Poirier, K., Mohiuddin, J. J., Maity, A. M., Facciabene, A., Amaravadi, R. K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac108 · Cited by 5
Novel approaches to promote CAR T-cell function in solid tumors
Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5
Metastatic melanoma: an AJCC review
Agarwala, S. S. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70491-0 · Cited by 5
General Principles of Tumor Immunotherapy
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15
Targeting precision medicine toxicity: recent developments
Mallarkey, G., & Mangoni, A. A. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614560737 · Cited by 5
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Lymphocytes T régulateurs
Aubin, F., & Saas, P. (2007) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(07)91612-9 · Cited by 4
Systemic therapy for melanoma.
Ganesan, P., & Bakhshi, S. (2010) · PubMed · Cited by 4
Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d’immunothérapie en onco-hématologie
Minard‐Colin, V. (2016) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2016.01.002 · Cited by 4
Novel Insights/Translational Implication from the Emerging Biology of Melanoma
Ribas, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_1 · Cited by 4
Self-citation
Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.02.022 · Cited by 4
Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review
Cheng, M., Zhang, S., Liu, J., Jiang, S., & Dong, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107703 · Cited by 4
The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives
Papadimitriou, M., Liakouli, Z., & PAPADIMITRIOU, C. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.138 · Cited by 4
Therapeutic Antibodies and Immunologic Conjugates
Dobrenkov, K., & Cheung, N. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00030-x · Cited by 4
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma
Cui, C., Li, J., Yang, Y., Si, L., Chi, Z., Mao, L., Wang, X., Tang, B., Yan, X., Li, S., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100638 · Cited by 4
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
Torino, F., Barnabei, A., Baldelli, R., & Appetecchi, M. (2012) · InTech eBooks · doi:10.5772/50375 · Cited by 4
Modelling Cancer Dynamics Using Cellular Automata
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2019) · STEAM-H: Science, Technology, Engineering, Agriculture, Mathematics & Health · doi:10.1007/978-3-030-15715-9_8 · Cited by 4
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity
Motofei, I. G. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2020243 · Cited by 5
Monoclonal Antibody Therapy of Cancer
Posada, J. G., & Frankel, A. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10055-x · Cited by 4
Agonistic antibodies to human glucocorticoid-induced tumor necrosis factor receptor as potential stimulators of T cell immunity for the treatment of cancer and viral infections
(2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.5.567 · Cited by 4
Translational Research in Melanoma
Tsai, S., & Sabel, M. S. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.12.003 · Cited by 4
Vaccine‐based approaches to squamous cell carcinoma of the head and neck
Zhang, X., Moche, J., Färber, D. L., & Strome, S. (2007) · Oral Diseases · doi:10.1111/j.1601-0825.2006.01329.x · Cited by 4
Melanoma vaccines – they should work
Danson, S. J., & Lorigan, P. C. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl055 · Cited by 4
Melanoma - Standard of Care, Challenges, and Updates in Clinical Research
Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100843 · Cited by 3
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
Zhou, C., Jiang, J., Xiang, X., Liu, H., Wu, G., Zeng, R., Lu, T., Zhang, M., Shen, Y., Hong, M., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00567-7 · Cited by 3
Newer developments in the immunotherapy of malignant melanoma
Maslin, B., Alexandrescu, D. T., Ichim, T. E., & Dasanu, C. A. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212472702 · Cited by 3
Antibodies to Stimulate Host Immunity
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00019-1 · Cited by 3
Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
Wang, A., Chu, H., Zheng, J., Jia, Q., & Zhu, B. (2021) · Disease Markers · doi:10.1155/2021/9453692 · Cited by 3
Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer
François, A., Descarpentrie, J., Badiola, I., Siegfried, G., Évrard, S., Pernot, S., & Khatib, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02073-1 · Cited by 3
Checkpoint Blockade Immunotherapy for Glioblastoma
Riccione, K. A., Gedeon, P. C., Sanchez-Perez, L., & Sampson, J. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00011-9 · Cited by 3
Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity
Guo, Q., Zhang, Z., Zhao, P., Zou, S., Li, L., Li, N., Sun, W., Wei, X., Hou, L., Yang, Z., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.12.010 · Cited by 3
Can we use monoclonal antibodies to help T cells fight tumors?
Barrett, A. J., & Wolchok, J. D. (2006) · Cytotherapy · doi:10.1080/14653240500518173 · Cited by 3
Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?
Tietze, J. K., Sckisel, G. D., Hsiao, H., & Murphy, W. J. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.598977 · Cited by 3
Malignes Melanom
Hallermann, C., Atzpodien, J., Klein, M., Krause‐Bergmann, A., Brodner, G., Strittmatter, G., Brunner, G., & Schulze, H.-J. (2009) · best practice onkologie · doi:10.1007/s11654-009-0186-4 · Cited by 3
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management
Eftekhar, S. P., Yazdanpanah, N., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1979396 · Cited by 3
Immune checkpoint inhibitors in renal cell carcinoma
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-2317-9 · Cited by 3
Pharmacogenetics and Pharmacogenomics I: Linking Diagnostic Classification to Therapeutic Decisions
Murphy, M. J., Pincelli, C., Hoss, D. M., & Borroni, R. G. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-171-4_21 · Cited by 3
Experimentelle Tumortherapie beim malignen Melanom und ihre Rationale
Rass, K., Diefenbacher, M. E., & Tilgen, W. (2008) · Der Hautarzt · doi:10.1007/s00105-008-1556-5 · Cited by 3
Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis
Yang, Y., Pei, J., Gao, G., Yang, Z., Guo, S., Yue, B., & Qiu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12644 · Cited by 2
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
Pardoll, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00052-4 · Cited by 2
Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers
Agarwal, R., Cangemi, N. A., Epstein, A. S., Harding, J. J., Reidy‐Lagunes, D. L., & Saltz, L. B. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz228 · Cited by 2
El español de los territorios del noroeste
Martínez, J. A. (1995) · Studia Academica: Revista de Investigación Universitaria · Cited by 2
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Wael, M., Wael, M., Hosam, M., Youssef, A., Ellackany, R., & Alzahabi, A. (2022) · Radiotherapy and Clinical Oncology · doi:10.31487/j.rco.2022.01.01 · Cited by 2
Transcriptional Profiles of Mart-1(27-35) Epitope Specific TCReng Human CD8+ and CD4+ T Cells upon Epitope Encounter as Elucidated by RNASeq
Singh, P. (2014) · Immunome Research · doi:10.4172/1745-7580.s2.004 · Cited by 2
YY1 expression and PD-1 regulation in CD8 T lymphocytes
Touboul, R., & Bonavida, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821909-6.00003-1 · Cited by 3
Drug Development in Cancer Medicine: Challenges for Targeted Approaches
Camacho, L. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_19 · Cited by 2
Self-citation
Frontiers in Cancer Immunotherapy
Murphy, J. F. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_1 · Cited by 2
Immunotherapy for Renal Cell Carcinoma
Davar, D., Fenton, M. J., & Appleman, L. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-062-5_16 · Cited by 2
The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward
Maio, M., Nicolay, H. J. M., Ascierto, P. A., Belardelli, F., Camerini, R., Colombo, M. P., Queirolo, P., Ridolfi, R., Russo, V. E. A., Anzalone, L., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-8 · Cited by 2
Overcoming viral escape with vaccines that generate and display antigen diversity in vivo
García-Quintanilla, A. (2007) · Virology Journal · doi:10.1186/1743-422x-4-125 · Cited by 2
Adjuvant Therapy for Cutaneous Melanoma
Tarhini, A. A., Moschos, S. J., & Kirkwood, J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1788-4.00053-8 · Cited by 2
Immunotherapy for Advanced Melanoma
Roman, R.-A. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e58-e65 · Cited by 2
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2
Selective Internal Radiation Therapy—Tackling the Tumor, Sparing the Organ
Miller, J. C., Blaszkowsky, L. S., Kalva, S. P., Radiology, I. I., & Medicine, I. I. (2008) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2008.04.1.68 · Cited by 2
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2
Safety Pharmacology: Similarities and Differences between Small Molecules and Novel Biopharmaceuticals
Bernton, E. W. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse173 · Cited by 2
On the fractional cell kill law governing the lysis of solid tumorsPreprint
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1601.07144 · Cited by 2
First world meeting of interdisciplinary melanoma/skin cancer centers
(2007) · Archives of Dermatological Research · doi:10.1007/s00403-007-0771-8 · Cited by 2
Effets endocriniens et métaboliques des immunothérapies anticancéreuses (d’après les recommandations de la Société française d’endocrinologie)
Wémeau, J.-L., BERTAGNA, X. Y., & Boîtard, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30188-8 · Cited by 1
Elucidating the role of medicinal plants in melanoma treatment: a review on metastatic progression and phytochemical intervention
Seaman, J. L., Twilley, D., & Lall, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1821643 · Cited by 1
Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview
Tarhini, A. A., & Kirkwood, J. M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_23 · Cited by 1
Targeted Agents for the Treatment of Melanoma: An Overview
Tseng, H., Li, W.-T., & Hsieh, J. (2013) · InTech eBooks · doi:10.5772/54938 · Cited by 1
Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer
Chmielowski, B., & Ribas, A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_48 · Cited by 1
Self-citation
Therapeutic Antibodies from XenoMouse Transgenic Mice
Jakobovits, A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596773.010 · Cited by 1
Neue Perspektiven in der immunologischen Krebstherapie
Rothschild, S. I., & Zippelius, A. (2012) · Therapeutische Umschau · doi:10.1024/0040-5930/a000330 · Cited by 1
Gezielte Therapie: alte und neue Hoffnungsträger
Hochhaus, A., Lüftner, D., & Mackensen, A. (2013) · Oncology Research and Treatment · doi:10.1159/000351997 · Cited by 1
Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules
Gauvain, C., Léna, H., Corre, R., Ricordel, C., Vinas, F., & CHOUAID, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2633-5 · Cited by 1
Strategies to Reduce Intratumoral Regulatory T Cells
Maherzi, C., Onodi, F., Tartour, É., Terme, M., & Tanchot, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_29 · Cited by 1
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K. D., & Shenton, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100601-6.02008-1 · Cited by 1
Ipilimumab
Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_11 · Cited by 1

Authors: Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., Sharma, A., Glaspy, J. A., & Gomez-Navarro, J.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Medicine, Division of Hematology/Oncology; Surgery, Division of Surgical Oncology and UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Departments of Experimental Therapeutics, Melanoma Medical Oncology and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Pfizer Global Research and Development, Groton-New London, CT
ORCID: Ribas, Antoni
Camacho, Luis H.
Reuben, James M.
Sharma, Amarnath
Glaspy, John A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-10
Volume: 23
Issue: 35
Pages: 8968-8977
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.109
OpenAlex: W2163184777
Cited by: 591
References: 31
Citations by year: 2026: 4 · 2025: 1 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 21 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 32 · 2016: 33 · 2015: 29 · 2014: 25 · 2013: 38 · 2012: 27
FWCI: 22.08
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: CTLA-4 blockade, melanoma, antitumor immunity, peripheral tolerance, autoimmune adverse events, maximum tolerated dose, dose-limiting toxicity, complete response, renal cell carcinoma, colon cancer, immunotherapy safety
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colonic Neoplasms, Female, Humans, Immune Tolerance, Immunotherapy, Infusions, Intravenous, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Proteins, Neoplasms, Regression Analysis, Antigens, CD, T-Lymphocyte Subsets, Treatment Outcome, Antibodies, Blocking, Cancer Vaccines, MART-1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks